cell and gene therapies | pharmaphorum

Sunday 22 December 2024

Channels

Content type

Categories

Categories

Sort by

Order

cell and gene therapies

News

Ryoncil in manufacturing

Mesoblast finally pushes GvHD cell therapy over finish line

At its third attempt, Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children.

Sales & Marketing

Happy lady reading from tablet

Coming soon: The Life Sciences Industry Report 2025 – insigh...

Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends

Market Access

illustration of hurdles increasing size

Overcoming regulatory hurdles to unleash breakthrough innova...

The life sciences industry is currently undergoing a significant transformation, driven by the rapid development of new modalities such as cell and gene therapies (CAGT), and substantial ne

Patients

patient support

Cell and gene therapies and the tricky question of patient s...

Cell and gene therapies represent the cutting edge of pharma technology, but how are patients experiencing this treatment revolution?

Market Access

cell and gene therapies

Collaboration is key to tackling geographical boundaries in ...

Unlike most biopharmaceuticals, it is often a struggle to manufacture cell and gene therapies (CGTs) in disparate geographies.

News

CGT production, MilliporeSigma

Merck builds in cell, gene therapies with Mirus Bio deal

Germany’s Merck KGaA has agreed to acquire Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies (CGTs), in a deal valued at a